SR9009 is a synthetic compound originally developed as a research tool to study the body’s internal clock, and it has never been approved for human use by any regulatory agency. First described in a 2012 study at the Scripps Research Institute, it was designed to activate proteins called REV-ERBα and REV-ERBβ, which help regulate circadian rhythms, fat storage, and inflammation. The compound gained attention after animal studies showed dramatic effects on metabolism and exercise endurance, but recent research has complicated the picture, revealing that SR9009 acts through pathways beyond its intended targets and raising questions about what it actually does inside cells.
What SR9009 Was Designed to Do
REV-ERBα and REV-ERBβ are proteins that function as part of the body’s circadian clock. They help switch genes on and off throughout the day, influencing when the body burns fat, stores energy, and cycles through sleep and wakefulness. The original idea behind SR9009 was straightforward: by activating these proteins with a drug, researchers hoped to manipulate circadian-linked metabolic processes on demand.
In the landmark 2012 mouse study, giving SR9009 to mice altered circadian behavior and changed the daily pattern of clock gene activity in the brain. It also reshaped the expression of metabolic genes in the liver, skeletal muscle, and fat tissue, leading to increased energy expenditure.1PubMed Central. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists That study painted a tidy picture: the drug flips the REV-ERB switch, and metabolism responds. The reality turned out to be messier.
The REV-ERB Problem
A 2019 study fundamentally challenged the assumption that SR9009’s effects flow through REV-ERB activation. Researchers engineered mouse cells that completely lacked both REV-ERBα and REV-ERBβ, then exposed those cells to SR9009. If the drug only worked by activating REV-ERBs, it should have done nothing. Instead, SR9009 still decreased cell viability, rewired cellular metabolism, and altered gene activity, even without its supposed targets present.2PubMed Central. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism The study’s conclusion was blunt: SR9009’s effects cannot be used as a stand-in for REV-ERB activity.
This finding matters beyond academic debate. It means the biological effects people attribute to SR9009 may partly stem from unknown, off-target mechanisms. When you don’t fully understand why a drug does what it does, predicting side effects in humans becomes much harder. And it complicates the narrative that SR9009 is a precise tool for circadian biology.
A 2022 study on heart function drove this point further. Researchers found that SR9009 protected mouse hearts against damage from pressure overload, but this cardioprotective effect persisted in mice whose heart cells had been genetically stripped of REV-ERBs entirely. The drug helped the heart regardless of whether its supposed target was present, and it worked the same way whether given at the time of day when REV-ERB levels peak or when they bottom out.3PubMed Central. SR9009 improves heart function after pressure overload independent of cardiac REV-ERB Whatever SR9009 is doing to the heart, REV-ERB activation alone doesn’t explain it.
Metabolic Effects in Animal Models
Despite the mechanistic uncertainty, the metabolic effects of SR9009 in rodents have been consistently striking across multiple labs. In one commonly cited set of experiments, a single injection triggered the expression of genes involved in fat burning and boosted mitochondrial activity in muscle. Twelve days of treatment increased energy consumption without changing the balance between fat and carbohydrate use, and after 30 days, mice could run significantly longer on a treadmill. Separately, treating mouse heart cells with SR9009 in the lab increased the number of mitochondria per cell.4Trends in Pharmacological Sciences. Exercise Pills: Is It Real? These findings earned SR9009 the “exercise in a bottle” label in the popular press, though that framing vastly oversimplifies what the studies actually showed.
On the fat metabolism side, SR9009 has reduced triglyceride levels and decreased the activity of enzymes responsible for building new fat.5PubMed Central. REV-ERBα Agonist SR9009 Promotes a Negative Energy Balance in Goldfish A more recent study found that chronic low-dose SR9009 could counteract weight gain and insulin resistance in mice exposed to constant light, a condition that disrupts their circadian rhythm and promotes metabolic dysfunction. The drug restored the expression of key clock genes in both white and brown fat tissue, particularly by suppressing a gene called Bmal1 and boosting REV-ERB expression.6PubMed Central. Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation
In atherosclerosis-prone mice lacking the LDL receptor, seven weeks of SR9009 at high doses reduced atherosclerotic plaque size by about 23% compared to untreated mice. The drug also shifted immune cells called macrophages away from a pro-inflammatory state and toward an anti-inflammatory one, suggesting effects on the immune system that go beyond simple fat-burning.7PubMed Central. Suppression of atherosclerosis by synthetic REV-ERB agonist
Effects on the Brain and Behavior
SR9009 also appears to affect the central nervous system in mice. In tests designed to measure anxiety, mice given the drug showed reduced anxiety-like behavior across multiple standard assays, including the open-field test, the light-dark transition test, and the marble-burying test.8Nature Communications. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour In a separate line of research, SR9009 suppressed neuroinflammation in the hippocampus of mice that had been given a compound to provoke an immune response, suggesting a potential role in dampening brain inflammation.9PubMed Central. Circadian clock protein Rev-erbα regulates neuroinflammation
Sleep is another area where animal data exist. Mice injected with SR9009 during their normal sleep phase showed increased wakefulness and decreased deep sleep and REM sleep. Over a few days of repeated dosing, these effects persisted without obvious short-term tolerance developing, meaning the mice didn’t seem to adapt to the drug’s wake-promoting effect. The sleep disruption also didn’t carry over into the animals’ next normal wake period, suggesting the effect wears off relatively quickly.10PubMed Central. Targeting the REV-ERBs in Sleep/Wake Regulation For anyone considering self-administration, this should be a red flag rather than a selling point: a compound that suppresses REM sleep in ways we don’t fully understand is not something you want to be experimenting with unsupervised.
Why No One Has Tested It in Humans
Given the list of seemingly beneficial effects in mice, a reasonable question is why SR9009 hasn’t moved to human clinical trials. The short answer involves a serious pharmacokinetic problem: the drug is very poorly absorbed and broken down rapidly in the body. Despite well-established effects in animal studies, no progress has been made in translating SR9009 to clinical trials, pointing to significant challenges in drug development for REV-ERB-targeting compounds.11PubMed Central. Targeting REV-ERBα for therapeutic purposes: promises and challenges
In most of the rodent studies, SR9009 was injected directly. Oral bioavailability is extremely low in mice, and there’s little reason to expect it would be better in humans. The compound is also metabolized quickly by liver enzymes. Research using human liver microsomes identified 13 metabolites of SR9009, generated primarily by four specific enzyme families (CYP3A4, CYP3A5, CYP2C19, and CYP2D6).12PubMed. A further insight into the metabolic profile of the nuclear receptor Rev-erb agonist, SR9009 This rapid breakdown means that even if you swallowed a capsule of SR9009, very little of the active compound would reach your bloodstream, and what did arrive would be cleared quickly.
Researchers are actively trying to solve this. One group synthesized a series of SR9009 analogues by modifying part of the molecule’s chemical structure. Several of these analogues matched or slightly exceeded SR9009’s potency at activating REV-ERBα in lab tests, and two of them showed stronger effects on blood sugar and lipid levels in mice with high cholesterol.13PubMed Central. Regulation of exercise ability and glycolipid metabolism by synthetic SR9009 analogues as new REV-ERB-α agonists But even these improved versions remain preclinical. The gap between “works in a mouse” and “safe and effective in a human” is enormous, and most compounds that look promising in rodents never make it across.
SR9009 Is Not a SARM
One of the most persistent misconceptions about SR9009 is that it belongs to the class of compounds known as SARMs (selective androgen receptor modulators). It does not. SARMs mimic the effects of testosterone by binding to androgen receptors. SR9009 has nothing to do with androgen receptors. The confusion arises because SR9009 is sold by many of the same online vendors that sell SARMs, often packaged and marketed in the same product lines. Analytical studies of products bought from supplement sellers have grouped SARMs, metabolic modulators like SR9009, and growth hormone secretagogues together as distinct categories of performance-enhancing compounds, and for good reason: they are different pharmacological classes that just happen to share a marketplace.14Wiley Online Library. SARMs, Metabolic Modulators and Growth Hormone Secretagogues in Suspected Illegal Medicines, Bought as Sport Performance Enhancers
This distinction matters practically. If you’re drawn to SR9009 because you think it will build muscle the way testosterone or SARMs do, the mechanism is completely wrong. Any endurance or body composition effects in animal studies relate to fat metabolism and energy expenditure, not anabolic muscle growth. And because it’s lumped together with SARMs in online retail, people sometimes apply SARM-related assumptions about dosing, cycling, and post-cycle therapy, none of which are relevant.
What Is Actually in the Products People Buy
SR9009 is widely available from online supplement and research chemical vendors, typically sold as capsules or liquid solutions with labels reading “for research use only.” That label exists because the compound has no regulatory approval for human consumption anywhere in the world. A comprehensive analysis of similar products purchased from Australian websites found that while most correctly listed the main active ingredient on the label, roughly 80% of them were contaminated with other performance-enhancing compounds. Only about a third of the products tested were considered of good quality in terms of dosage accuracy and consistency.15Performance Enhancement & Health. “For research use only”: A comprehensive analysis of SARMs and related IPEDs purchased on local Australian websites between 2017 and 2018
This means that if you purchase SR9009 from an online vendor, you face several layers of uncertainty. You don’t know whether the product actually contains SR9009 at the dose stated. You don’t know what else might be in it. And you don’t know what SR9009 does in the human body at any dose, because no controlled study has ever tested it. You’re combining an untested compound with an unregulated supply chain, which is about as far from evidence-based medicine as you can get.
Doping Status and Detection
The World Anti-Doping Agency (WADA) has listed SR9009 as a prohibited substance under the category of hormone and metabolic modulators. This applies both in and out of competition. Anti-doping laboratories have invested considerable effort into detecting it, not because its performance-enhancing effects are proven in humans, but because athletes are using it based on the animal data.
Detection methods have grown increasingly sophisticated. In equine racing, researchers identified a key metabolite (an N-dealkylated breakdown product called M1) and confirmed its presence in both plasma and urine doping samples from a horse that had been administered the drug. Low concentrations of the parent compound and additional metabolites were also detectable in plasma.16PubMed. In vitro metabolism of the REV-ERB agonist SR-9009 and subsequent detection of metabolites in associated routine equine plasma and urine doping control samples More recent work using advanced analytical techniques has identified 15 metabolites of SR9009 in horse liver preparations, including novel breakdown products that were previously unknown.17PubMed. Rapid investigating of phase I metabolites of SR9009 in vitro horse liver microsomes via feature-based molecular networking approach These efforts mean that anyone competing in a tested sport who takes SR9009 is very likely to be caught, and the detection window keeps widening as labs discover new metabolic markers.
What We Genuinely Don’t Know
The list of unknowns about SR9009 in humans is long enough that it should give anyone pause. There are no published data on human pharmacokinetics, meaning nobody has measured what blood levels you’d achieve from an oral dose, how long they’d last, or what metabolites would be produced. There are no human safety data, meaning nobody has systematically looked for liver toxicity, hormonal disruption, cardiac effects, or any other adverse outcomes in people. There are no human efficacy data, meaning the fat-burning, endurance-boosting, anti-inflammatory effects seen in rodents are exactly that: effects seen in rodents.
The REV-ERB-independent effects add another dimension of concern. If a meaningful portion of SR9009’s biological activity works through unknown pathways, then even the animal safety data, which are limited to begin with, may not capture the full range of what the drug does. A drug whose mechanism you don’t fully understand is one whose risks you can’t fully predict. The reduced cell viability observed in REV-ERB-knockout cells is a particularly uncomfortable finding: it suggests SR9009 can kill cells through pathways that have nothing to do with its intended target.2PubMed Central. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism
Researchers continue to investigate SR9009 and its analogues as potential leads for conditions ranging from obesity and type 2 diabetes to heart failure and neuroinflammatory diseases. Some of that research is genuinely promising at the preclinical level. But “promising preclinical candidate” and “safe for humans to self-administer” are separated by years of clinical trials, dose-finding studies, and safety monitoring that simply haven’t happened. The gap between those two things is where the real risk lives for anyone who decides to take SR9009 today.
SR9009’s Interaction with Circadian Timing
One detail that often gets lost in the performance-enhancement conversation is that SR9009 was originally conceived as a tool for studying circadian biology, and the timing of administration appears to matter in ways that researchers are still working out. The sleep study in mice found that the drug’s wake-promoting effects depended on when it was given: injections at certain points during the rest phase produced clear alertness and sleep suppression, while an injection at the transition point to the active phase did not.10PubMed Central. Targeting the REV-ERBs in Sleep/Wake Regulation Meanwhile, the cardiac study found no difference in cardioprotection between doses given at peak versus trough REV-ERB expression.3PubMed Central. SR9009 improves heart function after pressure overload independent of cardiac REV-ERB
This inconsistency reflects the broader puzzle: some of SR9009’s effects track with circadian timing (as you’d expect from a drug targeting clock proteins), while others don’t (consistent with the off-target activity). For the person buying capsules online and following a dosing protocol they found on a bodybuilding forum, this level of mechanistic uncertainty is practically invisible. But it means that even the animal researchers designing controlled experiments aren’t always sure what they’re looking at. The idea that a casual user could somehow dial in the right dose, at the right time, for the right effect, without any human pharmacokinetic data to guide them, asks for a level of precision that the science itself hasn’t achieved.